Stock IdeasStrong Buy StocksStrong Buy Stocks from Top Wall Street AnalystsLatest stocks with a Strong Buy rating from the top performing 25% of analysts tracked by WallStreetZen
Stock IdeasStrong Buy Stocks
| Analyst / Firm | Company | Price | Rating | Price Target | Upside/Downside | Date |
|---|---|---|---|---|---|---|
Ionis Pharmaceuticals IncIONS | $62.57 | Strong Buy | $86.00 | +37.45% | a day ago | |
Analyst RankingTop 11% #547 out of 5025 analysts Average Return+18.67% Win Rate50%39 out of 78 Risk vs RewardPoor Good Analyst ColorMorgan Stanley's Michael Ulz raised their price target on Ionis Pharmaceuticals (NASDAQ: IONS) by 21.1% from $71 to $86 on 2025/09/23. The analyst maintained their Strong Buy rating on the stock. On 2025/09/02, Ionis Pharmaceuticals announced positive topline results from its Phase 3 CORE and CORE2 studies of olezarsen in people with severe hypertriglyceridemia (sHTG). Ulz increased their U.S. olezarsen price projection for sHTG to $20,000, citing strong feedback from key opinion leader physicians and management's constructive comments at its Healthcare Conference regarding pricing leverage. | ||||||
Tesla IncTSLA | $800.00 | Strong Buy | $850.00 | +6.25% | a day ago | |
Upgrade to Premium to View MoreStrong buys: Upgrade to Premium to view the rest of today's Strong Buy stocks from Wall Street's top analysts Already have access to ? Sign In | ||||||
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.